Last edition
News about "neurodegenerative diseases "
NeuroSense Reports Positive Phase 2 Biomarker Results for PrimeC in Alzheimer's Disease Trial
PrimeC shows encouraging biomarker activity in Phase 2 Alzheimer’s study, supporting its potential as a multi-target therapy for neurodegenerative diseases.
Neurodegenerative Diseases | 26/06/2026 | By News Bureau | 175
Aphios Corporation has received a Notice of Allowance from the USPTO for a divisional patent application covering novel Bryoid compositions and manufacturing methods aimed at advancing therapies for neurodegenerative diseases, HIV latency and cancer.
Neurodegenerative Diseases | 29/05/2026 | By News Bureau
Denali Regains Full Rights to DNL593 After Takeda Ends Collaboration
The biotech firm will independently advance its investigational therapy for frontotemporal dementia, with Phase I/II trial results expected by 2026.
Neurodegenerative Diseases | 08/04/2026 | By News Bureau | 118
Alpha Cognition Secures US Patent for ALPHA-1062 in Traumatic Brain Injury Treatment
New patent protection through 2045 strengthens pipeline expansion beyond Alzheimer’s disease and targets unmet need in TBI therapeutics.
.
Neurodegenerative Diseases | 07/04/2026 | By News Bureau
Brenig Therapeutics Initiates First-in-Human Study of BT-409, Advances BT-267 Parkinson's Programme
Brenig Therapeutics has launched a first-in-human Phase I study of BT-409, a brain-selective NLRP3 inhibitor, while advancing BT-267 toward Phase 1b and Phase II studies in Parkinson’s disease.
Neurodegenerative Diseases | 20/01/2026 | By News Bureau | 365
Jaya Biosciences Receives US Patent for Novel Methods of Treating Neurological Diseases
US patent grant to Jaya Biosciences broadens protection and strengthens the company’s leadership in developing CNS-directed therapies for genetically defined neurodegenerative diseases.
Neurodegenerative Diseases | 07/11/2025 | By Dineshwori | 292
This marks the third collaboration BioArctic has entered into with partners using the BrainTransporter technology.
Neurodegenerative Diseases | 27/08/2025 | By Dineshwori | 434
Sanofi Acquires Vigil Neuroscience, Strengthens Neurodegenerative Disease Pipeline
Sanofi has completed its acquisition of Vigil Neuroscience, thereby strengthening its early-stage pipeline in neurology with the addition of VG-3927, an experimental drug candidate for Alzheimer's disease.
Neurodegenerative Diseases | 07/08/2025 | By Dineshwori | 335
Kadimastem Shareholders Approve Merger with NLS Pharmaceutics
The merger brings NLS and Kadimastem one step closer to creating a combined Nasdaq-traded biotechnology company with a robust portfolio of advanced therapies for neurodegenerative diseases and diabetes.
Neurodegenerative Diseases | 01/02/2025 | By Abha | 298
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy